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Abstract Cost-effectiveness analyses (CEAs) alongside
randomised controlled trials (RCTs) are increasingly
designed to collect resource use and preference-based
health status data for the purpose of healthcare technology
assessment. However, because of the way these measures
are collected, they are prone to missing data, which can
ultimately affect the decision of whether an intervention is
good value for money. We examine how missing cost and
effect outcome data are handled in RCT-based CEAs,
complementing a previous review (covering 2003–2009,
88 articles) with a new systematic review (2009–2015, 81
articles) focussing on two different perspectives. First, we
provide guidelines on how the information about miss-
ingness and related methods should be presented to
improve the reporting and handling of missing data. We
propose to address this issue by means of a quality eval-
uation scheme, providing a structured approach that can be
used to guide the collection of information, elicitation of
the assumptions, choice of methods and considerations of
possible limitations of the given missingness problem.
Second, we review the description of the missing data, the
statistical methods used to deal with them and the quality
of the judgement underpinning the choice of these meth-
ods. Our review shows that missing data in within-RCT
CEAs are still often inadequately handled and the overall
level of information provided to support the chosen
methods is rarely satisfactory.
Key Points for Decision Makers
This is the first systematic review proposing a quality
assessment of CEA studies based on how
missingness in costs and effects is handled and
reported (quality evaluation scheme, QES).
The recommendations, used in building the QES,
guide the choice of the missing data method based on
the description of the data and assumed missing data
mechanism; this in turn should be informed by the
available evidence and assessed using sensitivity
analysis.
The review shows a currently inadequate handling of
missingness for both outcomes in the literature.
This may in turn lead to bias or overconfidence in
CEA results that decision makers should take into
account in their evaluation of the quality of a study.
1 Introduction
A well-known issue in cost-effectiveness analysis (CEA),
especially within a randomised controlled trial (RCT) set-
ting, is the presence of large proportions of missing data in
either or both outcome variables, i.e. the cost and the
clinical effectiveness or utility measures. Removing the
unobserved cases (a method usually referred to as ‘‘com-
plete case analysis’’, CCA) generally leads to a loss in
& Andrea Gabrio
andrea.gabrio.15@ucl.ac.uk
1 Department of Statistical Science, University College
London, 1–19 Torrington Place, London WC1E 7HB, UK
2 Department of Health Services Research and Policy, London
School of Hygiene and Tropical Medicine, 15–17 Tavistock
Place, London WC1H 9SH, UK
PharmacoEconomics Open
DOI 10.1007/s41669-017-0015-6
efficiency and possible serious biases in the parameter
estimates [1–4]. Consequently, the final conclusions of the
study may be strongly influenced by the way in which
missingness is handled, thus possibly reversing the deci-
sion about the cost-effectiveness of a new treatment com-
pared with the standard option [5, 6].
While the problem of missing data is widely discussed
in the general statistical literature, it has been less exten-
sively addressed in the health economics one. Notable ex-
ceptions include Graves et al. [7], Briggs et al. [8],
Oostenbrink et al. [9], Oostenbrink et al. [10], Burton et al.
[11] and Lambert et al. [12], mainly focussing on the cost
measures; Richardson and Manca [13], Wood et al. [14],
Groenwold et al. [15], Powney et al. [16], Simons et al.
[17] and Rombach et al. [18], with reference to health
outcome measures; and Manca and Palmer [5], Harkanen
et al. [19], Diaz-Ordaz et al. [20] and Faria et al. [21], who
consider both outcomes.
Interestingly, recent reviews on the methods applied in
within-trial CEAs [22–24] have concluded that CCA has
historically represented the standard approach in health
economics. As a result, we should be naturally sceptical
about the conclusions achieved by CEAs performed in a
context where missingness is not addressed in a ‘‘princi-
pled’’ way. We make reference to the concept of a prin-
cipled approach to handle missingness in Sect. 2. Within
this framework, subsequent inferences are valid under the
stated assumptions, which in turn can be varied to test their
impact on the decision-making.
The objective of this article is twofold: first, we collect
guidelines from the literature about the way in which
missingness should be analysed and reported in within-trial
CEAs and embed them within a structured scheme. Sec-
ond, we review the methods used to handle missingness in
the studies between 2003–2015 by updating and extending
the work of Noble et al. [22]. This is done with a view to
assessing whether the methods have evolved over time and
whether the quality level of missing data analyses is ade-
quate. The paper is structured as follows: Sect. 2 illustrates
Rubin’s classification of missing data mechanisms [1]. In
Sect. 3, we provide a brief summary of the most popular
missingness methods. In Sect. 4, we provide a structured
approach, which we name quality evaluation scheme,
which summarises the most important recommendations
collected from literature about the way information and
assumptions on missing data should be provided in CEA
studies. Based on these guidelines, we also suggest a sys-
tematic approach for grading the studies given the overall
level of information about missingness provided. Section 5
presents the methodology used to select the review’s arti-
cles and the main results derived from the different
descriptive analyses performed. In Sect. 6, we apply the
quality evaluation scheme to the reviewed articles in the
period 2009–2015 and show how they perform in terms of
missing data handling. Finally, Sect. 7 summarises our
findings and recommendations.
2 Missing Data Mechanisms
When analysing partially observed data, it is essential to
investigate the possible reasons behind the missingness.
This formally translates into an assumed missing data
mechanism that is linked to the data generating process, as
a key concept to address missingness in a ‘‘principled’’
way. We specifically refer to ‘‘principled’’ methods for
missing data as those based on a well-defined statistical
model for the complete data, and explicit assumptions
about the missing value mechanism.
We consider a sample of i ¼ 1; . . .; n individuals; for
each, the relevant outcome is indicated as yi, which is
unobserved for some individuals. Typically, trial data also
include a set of J covariates xi ¼ ðx1i; . . .; xJiÞ, e.g. sex, age
or co-morbidities. While in general these may be partially
or fully observed, in this section we consider only the latter
case. In addition, we define a missingness indicator mi
taking value 1 if the ith subject is associated with missing
outcome and 0 otherwise.
This setting can be modelled using two sub-models, or
‘‘modules’’. The first module is the missing data mecha-
nism, denoted as model of missingness (MoM). It describes
a probability distribution for mi, as a function of some
unobserved parameters pi and d, defining the probability of
missingness in the outcome variable yi. The second module
is the data generating process of the outcome variable,
denoted as model of analysis (MoA). This contains the
main parameters of interest (e.g. the population average
costs and benefits) and describes a probability model for
the outcome yi. As a general example, we can think of a
simple regression model where yi N ðli; rÞ, and
li ¼ b0 þ b1xi. In this case, the parameters of the MoA are
the regression coefficients b ¼ ðb0; b1Þ representing
respectively the intercept and the slope, and the individual
standard deviation r.
The most accepted classification of missingness mech-
anisms is given by Rubin [1] and is based on three classes,
according to how the missingness probability in the MoM
is modelled. A simple graphical representation of the three
classes is provided in Fig. 1. Variables and parameters are
denoted by nodes of different shapes and colours according
to their nature. Parameters (b0, b1, r, d) are represented
through grey circles. ‘‘Logical’’ quantities such as li and
pi, which are defined as a function of other parameters, are
denoted by a double circle notation. Fully observed vari-
ables (mi) are represented with a white circle, while par-
tially observed variables (yi) are denoted by a darker grey
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circle. Finally, we show covariates (xi) as white squares to
indicate that they are fully observed and not modelled.
Rounded rectangles are used to show the extent of the two
modules in terms of variables/parameters included. Arrows
show the relationships between the nodes, with dashed and
solid lines indicating logical functions and stochastic
dependence, respectively.
Figure 1a illustrates the class of ‘‘missing completely at
random’’ (MCAR), in which the probability of missingness
is fully independent of any other partially or fully observed
variable. Consequently, in Fig. 1a, MoA and MoM are not
connected and pi does not depend on any quantity in the
MoA. This amounts to assuming that there is no systematic
difference between partially and fully observed individuals
in terms of the outcome yi. In other words, in this case, we
would be assuming that observed cases are a representative
sample of the full sample.
Figure 1b shows a case of ‘‘missing at random’’ (MAR),
in which the missingness probability may depend on a fully
observed variable. As a result, MoA and MoM are con-
nected by means of the predictor variable affecting both the
mechanisms generating yi and mi. Because of this rela-
tionship, the partially observed cases are systematically
different from the fully observed cases; crucially, however,
the difference is fully captured by xi.
Figure 1c provides an example of ‘‘missing not at ran-
dom’’ (MNAR). This is characterised by dependence of the
probability of missingness on both the partially and fully
observed variables. Thus, in Fig. 1c, pi depends on both the
fully observed predictor xi and the partially observed out-
come yi. This means that the difference between fully and
partially observed cases still depends on the missing values,
even after taking xi into account. Therefore, it is necessary to
make more structured assumptions about this relationship
that go beyond the information contained in the data.
While intuitively helpful, this framework may be too
simplistic in some cases. Since the scope of this section is to
provide a broad overview for Rubin’s classification, we
β
μi
σ yi
xi πi
δ
mi
MoA
MoM
(a) Missing Completely At Random
(MCAR)
β
μi
σ yi
xi πi
δ
mi
MoA
MoM
(b) Missing At Random (MAR)
β
μi
σ yi
xi πi
δ
mi
MoA
MoM
(c) Missing Not At Random (MNAR)
Fig. 1 Graphical representation of Rubin’s missing data mechanism
classes, namely MCAR (a), MAR (b) and MNAR (c). Variables and
parameters are represented through nodes of different shapes and
colours. Parameters are indicated by grey circles with logical
parameters defined by double circles, while predictor variables are
assumed fixed and drawn as white squares. Fully observed variables
are denoted by white circles, partially observed variables by darker
grey circles. Nodes are related to each other through dashed and solid
arrows which respectively represent logical functions and stochastic
dependence. MoA model of analysis, MoM model of missingness
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assumed the simplest case where missingness is present in a
single response variable only, which may not hold in real
applications. This is particularly likely in the context of
CEA, in which we are concerned with a multivariate out-
come, made of suitable measures of clinical benefits and
costs, i.e. yi ¼ ðei; ciÞ. Missingness can occur for either or
both the relevant outcomes, and this can lead to as many
missingness mechanisms as the number of partially observed
quantities (covariate missingness must also be considered).
Additional complexity is given by whether data are obtained
in a cross-sectional or longitudinal setting, static or time-
varying covariates and more importantly the possible cor-
relation between variables and missingness mechanisms and
between the mechanisms themselves.
3 Approaches to Handle Missing Data
There are many different statistical approaches to deal with
missingness, each relying on different assumptions. It is
important to carefully select the approach in line with the
setting-specific assumptions we assume to hold. For the
sake of simplicity here we only broadly categorise these
techniques. More in-depth and complete presentation and
analysis can be found for example in Molenberghs et al. [4]
and Schafer and Graham [25].
3.1 Complete Case Analysis
This is a popular method in within-trial CEA studies,
despite its limitations due to the strong assumption that
only the fully observed cases are needed in order to cor-
rectly make inference. The critical disadvantage is that
missing cases are simply discarded, thus reducing effi-
ciency and possibly biasing the parameter estimates.
3.2 Single Imputation
Single imputation (SI) methods replace the missing data with a
single predicted value, such as the unconditional or condi-
tional mean or the last value observed for a given case. This
category includes last value carried forward [26], linear
extrapolation [27], mean and conditional imputation [28].
Although sometimes valid, these methods are never recom-
mended, as they typically require stronger assumptions than
MCAR and always fail to take account of the uncertainty
underlying the imputation process; i.e. they do not recognise
that the imputed values are estimated rather than known.
3.3 Multiple Imputation
A more sophisticated method is multiple imputation [MI,
1]. The underlying idea is to fill in the missing data with
plausible simulated values, drawn from the conditional
predictive distribution of the missing given the observed
values. Thus, the set of imputations can properly represent
the information about the missing values that is contained
in the observed data for the chosen model. This is repeated
K times, leading to K imputed datasets that can be analysed
via complete-data methods. The individual estimates are
then combined into a single quantity, e.g. using Rubin’s
rules [1]; this captures the variability within and between
imputations. However, the critical aspect is that valid
inferences depend on the correct specification of the
imputation model in terms of variable selection, distribu-
tions and correlations.
3.4 Sensitivity Analysis
Sensitivity analysis (SA) is a technique used to determine
how different input values in a model will impact the
output, under a given set of assumptions. Missing data will
invariably increase the underlying uncertainty, because
they induce a lower level of information in the data. SA
represents an extremely valuable tool to deal with the
uncertainty induced by missingness. Indeed, when applied
specifically to missing data, SA corresponds to exploring as
many plausible missing data assumptions as possible and
then assessing how consistent results are across the dif-
ferent scenarios. In particular, it is generally recommended
to set MAR as the reference assumption and then explore
different MNAR departures from MAR, to assess the
robustness of the results to different plausible alternative
missingness mechanisms. The purpose of such analysis is
to account more fully for the uncertainty about the miss-
ingness. Usually SA is implemented through more
advanced methods that are able to explicitly model a
MNAR mechanism such as selection or pattern mixture
models [4, 30].
3.5 Others
Examples of other less commonly adopted methods that we
found in the reviewed articles were: random draw, linear
mixed-effects model [31], expectation-maximisation algo-
rithm [32], input-case analysis, assumed zeros and two-part
regression.
3.6 Alternatives
There is a long list of possible alternatives that could be
explored. Among the most important we refer to inverse
probability weighting [33], data augmentation [34], likeli-
hood-based methods [35] and doubly robust [36] and full
Bayesian methods [30, 37].
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4 Recommendations for Missing Data Analyses
The main contribution of this paper to the literature for
missing data analysis recommendations is provided by
the quality evaluation scheme, as a structured reporting
and analysis system which aims to embed all the most
important guidelines for authors in terms of missing data
handling in CEA. These are listed in Table 1 and sum-
marise the guidelines provided by previous review arti-
cles [14, 21–23]. The contribution of the scheme consists
in providing a unique, general and structured framework
that authors can use to more easily check that all the
relevant information about missing data is used to
inform the assumptions relating to the missing data in
their analysis.
4.1 Quality Evaluation Scheme
In order to judge whether missing data in CEAs have been
adequately handled, a full description of the missingness
problem, details of the methods used to address it and a
discussion on the uncertainty in the conclusions resulting
from the missingness are required. With this in mind, we
have assembled guidelines on how information relating to
the missing data should be reported (Table 1). We define
three broad categories (description, method, limitations).
For each, information that we consider vital for
transparency is listed under ‘‘key considerations’’, while
other details that could usefully be provided as supple-
mentary material are suggested under ‘‘optimal
considerations’’.
Using the list of key considerations in Table 1, one first
determines whether no (all key considerations absent),
partial (one or more key considerations absent) or full (all
key considerations present) information has been provided
for each component. From this, one computes a numerical
score to summarise the overall information provided on
missingness, weighting the components in a ratio of 3:2:1.
This weighting scheme has been chosen based on some
reasonable assumptions in terms of how the different
analysis components could impact the results in terms of
missing data handling. Specifically, we think the ‘‘limita-
tions’’ component should not be weighted as much as the
other two because of its limited impact on the conclusions.
In the same way, we suggest that the ‘‘description’’ should
be weighted more than the ‘‘method’’ component, as it
generally drives the choice for the initial assumptions about
the missingness. We are aware that other weighting
schemes could be chosen, but in light of the given con-
siderations, we think the proposed weights are a reasonable
choice that we recommend. In addition, the robustness of
the scheme to a different weight choice, where each
component has exactly the same weight, has been tested to
assess the sensitivity of the score assignment. While the
Table 1 List of information content for each of the three components
that one would like to observe in the studies to achieve full analysis
reporting of missing data. The contents are divided into two
subgroups: key and optimal considerations. The former are the
statements to be considered as mandatory for transparency when
conducting an economic evaluation in the presence of missing data.
The latter are additional considerations that further extend the
analysis reporting of the missing data through supplementary
materials. The lack of even one single key consideration is considered
to indicate partial analysis reporting, while null analysis reporting is
related to the absence of all key considerations
Description Method Limitations
Key considerations Key considerations Key considerations
1. Report the number of individuals with missing
data for each variable in the reported analysis
by treatment group
1. Identify a plausible missingness assumption for the
specific patterns and setting analysed
1. Acknowledge and quantify
the impact of the missing data
on the results
2. Describe the missing data patterns for all
variables included in the economic analysis (is
missingness on one variable associated with
missingness on another variable? Is there a
longitudinal aspect to the data?)
2. State the method and software used in the base-
case analysis
2. State possible weaknesses
and issues with respect to the
method and assumptions
3. Discuss plausible reasons why values are
missing (e.g. death)
3. For more general methods, provide details about
their implementationa
4. Perform a plausible robustness analysis; provide
and discuss the results
Optimal considerations Optimal considerations
1. Provide supplementary material about the
preliminary analysis on missingness
(e.g. descriptive plots and tables)
1. Provide supplementary material about the method
implementation in the base-case and robustness
analysis (e.g. software implementation code)
a For example, in multiple imputation, state the imputation model specification and variables included, the number of imputations, post
imputation checks
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results do not show any significant changes in the classi-
fication of the articles, when using the alternative scheme,
it is more difficult to discriminate across the articles due to
a more limited score range.
Finally, one converts the scores into grades A–E. The
relevance of the scores, and of the derived grades, in terms
of decision analysis is mainly associated with a qualitative
assessment of the articles. Studies that are graded in the top
categories should be associated with a higher degree of
confidence in their results, whereas more caution should be
taken in the consideration of results coming from studies
that are graded in the bottom categories. When qualita-
tively assessing the articles, the different grading assigned
to each of them could be an indication of a lack in the
robustness of the conclusions provided due to missingness
uncertainty.
Figure 2 shows the process and weights used. Although
the importance between the different components is sub-
jective, we believe that the chosen structure represents a
reasonable and relatively straightforward assessment
scheme.
The resulting scores can be interpreted as follows:
A (12) The highest quality judgement, identified by the
upper thicker blue path in Fig. 2, including only those
studies that simultaneously provide all the key consid-
erations for all the components. It is the benchmark for a
comprehensive explanation and justification of the
adopted missing data method.
B (9–11) Includes studies providing full details for either
the description or the method and at least partial
information for the other components. Studies with no
information about the limitations are only included in
this category if full detail is provided for both the other
components.
C (6–8) Studies for which information about missing-
ness is not well spread across the components. All key
considerations are provided either for the description or
the method, but with only partial or no content in the
other components. Alternatively, we can have partial
content for description and method, and partial or full
content for limitations.
D (3–5) Indicates a greater lack of relevant information
about missingness. Despite possibly including key
considerations on any of the components, the informa-
tion provided will at most be partial for the description,
in which case it will be combined with a total lack of
content on either the method or the limitations.
E (0–2) The worst scenario, where the overall informa-
tion about the missing data is considered to be totally
unsatisfactory. No description is given, and we can
observe at most only some of the key considerations for
the method.
5 Literature Review
5.1 Methods
Noble et al. [22] (henceforth NHT) reviewed the methods
used to handle missing cost measures in 88 articles pub-
lished during the period 2003–2009. We extend their
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CONTENT
SCORE
Description Method Limitations
Full (F) 6 4 2
Partial (P) 3 2 1
Null (N) 0 0 0
Fig. 2 Diagram representation for the quality score categories. The
table at the bottom shows how scores have been weighted according
to the information provided on each component. In accordance with
the table, different branches of the diagram correspond to different
components. From left to right, the initial branches are related to the
description, branches in the middle to the method, and final branches
to the limitations. The branches’ colour represents the different way
the information provided in each analysis component is evaluated: red
no information (N), light blue partial information (P), blue full
information (F). Final scores (0–12) with associated ordered
categories (E–A) show the overall level of information provided for
each combination of component and content evaluation
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review, to include missing effects. Further, we use NHT’s
strategy to identify papers in the subsequent period, 1 April
2009 to 31 December 2015. Articles were considered eli-
gible for the review only if they were cost-effectiveness
analyses within RCTs, used individual patient-level data
and mentioned missing data in the text. We relied on
the search engines of three online full-text journal reposi-
tories: (1) Science-Direct.com, (2) bmj.com, and
(3) The Database of Abstracts of Reviews of Effects
(DARE) and NHS Economic Evaluation Database (NHS
EED). The key words used in the search strategy were
(cost effectiveness OR economic evalua-
tion) AND missing data AND trial AND
(randomised OR randomized). The on-line databases
identified 1129 articles, most of which were duplicates.
After abstract review, 128 articles were considered, of
which 81 fulfilled the eligibility criteria.
We present and compare the articles reviewed for the
two periods by type of analysis performed. First, we look at
the base-case methods implemented, i.e. those used in the
main analysis embedding the assumptions about missing
data. Second, we consider any alternative methods dis-
cussed; when present, these assess the robustness of the
results obtained in the main analysis against departures
from the initial assumptions on missingness.
5.2 Base-Case Analysis
As shown in Fig. 3a, NHT found that CCA was the most
popular base-case method, used in 31% of the papers; 23%
were unclear about the technique adopted. Single imputa-
tion methods were well represented, with mean imputation
and conditional imputation used in 10 and 9% of the arti-
cles, respectively. MI was found in 9% of the articles. Our
analysis of the methods for missing effectiveness measures
shows a similar pattern in Fig. 3c. CCA was used in 27% of
the cases and with a sizeable proportion of papers unclear
about the technique adopted (24%). Single imputation
methods are here dominated by last value carried forward
(LVCF) (10%), while a slightly higher proportion uses MI
(15%).
In 2009–2015, MI replaces CCA as the most frequently
used base-case method in both costs and effects, at 33 and
34%, respectively (Fig. 2b, d). However, CCA is still the
method of choice in many papers (15% for costs and 21%
for effects). The proportion of papers that are unclear about
the chosen method is similar over the two time periods for
costs, but halves in the later period for effects. This is
plausible since clinical effectiveness measures and the
estimate of treatment effect have been the main focus of
the analyses, whereas costs are less frequently included as a
primary outcome in the study research questions. This will
translate into a more careful and reasoned examination of
the missingness problem in the effect compared with the
cost analysis.
5.3 Robustness Analysis
With the term ‘‘robustness analysis’’ we refer to a different
concept with respect to the one introduced in Sect. 3.4. In
particular, we make this distinction so we can specifically
refer to robustness analysis as any alternative analysis,
compared with the base-case analysis, based on different
missing data methods. By contrast, when applied to miss-
ing data, SA can be thought of as structurally varying the
assumptions about the missingness model, whose plausi-
bility can be assessed in light of known information.
However, in practice, even robustness analyses are
rarely performed in CEAs. This poses an important ques-
tion related to the reliability of the findings, as they may be
affected by the specific assumptions about the missing data.
From both review periods it seems that a robustness anal-
ysis is infrequently used and typically involves only one
alternative scenario. This is not likely to be an optimal
choice as the main objective of this analysis is to explore as
many plausible alternative missing data assumptions as
possible.
NHT found that 75% (66/88) of the articles did not
include any robustness analysis, with the remaining papers
typically performing an analysis by comparing CCA and
MI (based on missing costs only). Similar findings apply to
missing effects, with about 76% (67/88) of the studies
lacking any alternative missing data method. Similarly, in
the 2009–2015 review, we observe no robustness analysis
in the majority of the articles for both costs (75% or 61/81)
and effects (70%, 51/81).
Figure 4 provides a pictorial overview of the alternative
methods used for cost and effect data. For costs, most
articles describe no alternative analysis. In the earlier
period, the choice of alternative missingness methods
seems well spread across CCA, MI and the use of more
than one method, with a slightly more frequent adoption of
MI. By contrast, in the later period, more cases use CCA as
a robustness method in combination with MI as the base-
case method.
Figure 4c, d describes the effects, with most of the
articles not reporting any robustness analysis and with a
significant decrease in MI analyses used for robustness,
opposed to an increase in CCA, between the two periods.
There is a similar pattern to the cost graphs towards CCA
used as a robustness method in combination with MI as the
base-case method.
One of the possible reasons that lead authors to use CCA
as a robustness method is its simplicity of implementation.
Although in many cases its underlying assumptions may
not be credible, authors may use it to make comparisons
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with the base-case method as it is a quick and easy-to-
perform alternative option.
6 Grading the Articles
Comparing the information provided in the articles in our
review against the list given in Sect. 4.1 allows us to
qualitatively assess the quality of the reporting of how
missingness has been handled in the reviewed CEA studies.
To gain a fuller understanding of the current state of
play, we also classify the articles from the perspective of
the strength of the assumptions about the missingness
mechanism. This is related to the choice of method, since
each is underpinned by some specific missing data
assumption. We can view the quality judgement and
strength of assumptions as two dimensions providing a
general mapping of how the missingness problem is han-
dled. This applies to both the level of knowledge about the
implications of a given missingness assumption on the
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(c) Missing eﬀects (2003-2009)
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Fig. 3 Review of base-case methods used to handle missing cost and
effect data between 2003–2009 and 2009–2015. Legend: complete
case analysis (CCA), last value carried forward (LVCF), linear
extrapolation (Lin Ext), mean imputation (Mean), conditional impu-
tation (Cond), multiple imputation (MI), any other method present in
fewer than four articles (Others), unspecified method (Unclear). The
category ‘‘Unclear’’ includes those articles for which it was not
possible, based on the text, to understand the methodology used to
deal with the missingness, while the category ‘‘Others’’ consists of the
following methods: random draw, linear mixed-effects model,
expectation-maximisation algorithm, input-case analysis, assumed
zeros, two-part regression. The numbers to the right of the bars in the
graphs are the number of papers including the corresponding method
in the base-case analysis
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results and how these are translated into the chosen
method. Details of our evaluation of both aspects are
provided next, starting with the strength of assumptions.
We group the methods into five categories, broadly
ordered according to the strength of the associated miss-
ingness assumptions. These are: single imputation (SI);
complete case analysis; multiple imputation; and unknown
(UNK), a residual group in which we classify studies that do
not explicitly mention the method used. We associate this
class with the strongest level of assumptions, since the lack
of any method description may implicitly suggest (over)-
confidence in a small effect of missingness on the results. By
contrast, we define sensitivity analysis (SA) as the least
restrictive approach, which can assess the robustness of the
results to different alternative missing data assumptions.
Figure 5 gives a graphical representation of both aspects
for the articles reviewed between 2009–2015 in terms of
the assumptions and justifications (quality scores) on
missingness. In both graphs, more studies lie in the lower
than in the upper part, indicating that fewer studies can be
classified as high quality in terms of the considerations
about missingness. This is highlighted by a greater con-
centration of points at the bottom of the figures (grade E).
As we move along the vertical axis, this tends to reduce up
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Fig. 4 Comparison of methods used in the base-case analysis (x axis)
and those used as alternatives in a robustness analysis (y axis) for the
articles between 2003–2009 and 2009–2015 for missing costs and
effects. Legend: unspecified methods (Unclear), other methods
(Others), linear extrapolation (Lin Ext), last value carried forward
(LVCF), mean imputation (Mean), conditional imputation (Cond),
complete case analysis (CCA), multiple imputation (MI). The
category ‘‘Unclear’’ includes those articles for which it was not
possible, based on the text, to understand the methodology used to
deal with the missingness, while the category ‘‘Others’’ consists of the
following methods: random draw, linear mixed-effects model,
expectation-maximisation algorithm, input-case analysis, assumed
zeros, two-part regression
Handling Missing Data: A Review and Guidelines
to the top level (grade A), where only very few cases are
shown. Of particular interest is the (almost) total absence
of articles that performed a sensitivity analysis (SA),
clearly indicating very slow uptake of this technique.
A shift along the vertical axis in the graphs indicates an
increase in the level of understanding about the implica-
tions for the results of different choices of the missing data
assumptions. Therefore, we can argue that an upward
movement in the plot will always improve the justification
of a specific assumption. However, to be able to follow this
path, we may have to rely on more sophisticated methods
that can match the given missingness assumption; e.g. if
we think our data are MNAR, then CCA assumptions are
less likely to hold. The aim of an optimal analysis should
be to select a method that can be fully justified by matching
the description of the missing data problem to the
assumptions underpinning the chosen method, i.e. map
onto the upper section of the graphs.
As a concrete example about the importance of exploring
different missingness assumptions in terms of the impact
they may have on the CEA, we consider one of the reviewed
studies that has been graded as ‘‘A’’ by our scheme [187].
The authors provide an assessment of the probability of
accepting a given treatment against a comparator (CEAC)
for different willingness to pay thresholds and missingness
methods. For all the thresholds considered, substantial
uncertainty is reflected by significant variations in the CEAC
values according to the different missing data methods used.
Specifically, the incorporation of external information leads
to missingness assumptions that significantly affect the
uncertainty in the results, producing a decrease in the value
of the CEAC, at the target willingness to pay threshold, from
71% in the base-case (CCA) to 53% in one alternative
scenario (MI). This example should encourage authors to
recognise the importance that a comprehensive examination
of missingness via SA may have on the uncertainty around
CEA conclusions.
7 Discussion
The objective of this paper is to critically appraise the issue
of missing data analysis in within-trial CEAs. In addition,
we aim at providing a set of recommendations to guide
future studies towards a more principled handling and
reporting of missingness. It is important that assumptions
about missing data are clearly stated and justified. Sensi-
tivity analysis is also important, in order to explore the
impact of plausible alternative missing data assumptions on
the results of the CEA. Often, a variety of techniques and
analyses are used but not reported because of space limits;
on-line appendices and supplementary material could be
used to report these alternatives.
7.1 Descriptive Review
Figure 3 highlights a shift in the most popular base-case
missingness method from CCA to MI, between the two
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Fig. 5 Joint assessment, in the reviewed articles between 2009–2015,
for missing costs and effects, of two components. The x-axis is the
missingness method assumptions: unknown (UNK), single imputation
(SI), complete case analysis (CCA), multiple imputation (MI) and
sensitivity analysis (SA). The y-axis is the ordered classification for
the quality judgement (scores) to support these assumptions: E, D, C,
B, A
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periods of the review. The reasons behind this change may
be related to some drawbacks of CCA and the relatively
recent wide development of software to perform MI.
First, even under a strong missing data assumption
such as MCAR, CCA remains inefficient because it
ignores the predictive information contained in the par-
tially observed cases. Non-negligible rates of missingness
on a few variables of interest may cause large portions of
the sample to be discarded. Second, CCA may cause
serious biases in the parameter estimates. Indeed, the
condition for validity of CCA does not fit neatly into
Rubin’s classes [38] in the important cases when: missing
data affect the covariates; or the partially observed out-
come has a longitudinal nature.
Arguably, a very important factor in the increasing
popularity of MI is the recent availability of specific
computer routines or packages (e.g. STATA or R; see [2]).
This probably led to some abuse of the method as noted by
Molenberghs et al. [4]. On the one hand, MI generally
allows the inclusion of a larger number of variables/pre-
dictors in the imputation model than used in the analysis
model, which potentially makes the assumption of MAR
more plausible and thus the overall analysis less likely to
be biased. On the other, the performance of MI depends on
the correct specification of the imputation model (i.e.
complexity in the analysis model is reflected in the impu-
tation model) and care is required in its construction.
Although essential, these details can be overlooked and are
not often included in the reporting of the analysis, under-
mining its reliability.
From the comparison of the base-case methods used for
the costs and effects between 2009 and 2015 (Fig. 3), we
observe a marked reduction in the number of methods not
clearly described for the effects, compared with those for
the costs. A possible reason for this is that, while clinical
effectiveness measures are often collected through self-
reported questionnaires, which are naturally prone to
missingness, cost measures rely more on clinical patient
files, which may ensure a higher completeness rate. It was
not possible to confirm this interpretation in the reviewed
studies due to the high proportions of articles not clearly
reporting the missing rates in both 2003–2009 and
2009–2015 periods, for effect (45 and 38%) and cost
data ( 50 and 62%). In addition, clinical outcomes are
almost invariably the main objective of RCTs, and as such
they are usually subject to more advanced and standardised
analyses. Arguably, costs are often considered as an add-on
to the standard trial: for instance, sample size calculations
are almost always performed with the effectiveness mea-
sure as the only outcome of interest. Consequently, missing
data methods are less frequently well thought through for
the analysis of the costs. However, this situation is likely to
change as cost data from different perspectives (e.g.
caregivers, patients, society, etc.) are being increasingly
used in trials, leading to the more frequent adoption of self-
report cost data, which may start to exhibit similar miss-
ingness characteristics to effect data.
Our review identified only a few articles using more
than one alternative method (Fig. 4). This situation indi-
cates a gap in the literature associated with an under-im-
plementation of sensitivity analyses, which may
significantly affect the whole decision-making process
outcome, under the perspective of a body who is respon-
sible for providing recommendations about the imple-
mentation of alternative interventions for health care
matters.
Limiting the assessment of missingness assumptions to a
single case is unlikely to provide a reliable picture of the
underlying mechanism. This, in turn, may have a signifi-
cant impact on the CEA and mislead its conclusions,
suggesting the implementation of non-cost-effective treat-
ments, whose definition will depend on the assumption the
modeller thinks is more likely to hold in the given setting.
Sensitivity analysis represents an important tool to properly
account for more structured uncertainty related to the
missing data, and its implementation may provide a more
realistic picture of the impact that the assumptions have on
the final conclusions.
7.2 Quality Assessment
Despite the fact that our quality evaluation scheme has not
been tested/validated by independent assessors, we believe
Sect. 4.1 provides some reasonable justification for its
application to the reviewed articles. Generally speaking,
most papers in our review achieved an unsatisfactory
quality score under our classification (Fig. 5). Indeed, our
benchmark area on the top-right corner of the graphs is
barely reached by less than 7% of the articles, for both cost
and effect data. The opportunity of reaching such a target
might be precluded by the choice of the method adopted,
which may not be able to support less restrictive assump-
tions about missingness, even when this would be desir-
able. As a result, when simple methods cannot be fully
justified, it is necessary to replace them with more flexible
ones that can relax assumptions and incorporate more
alternatives. In settings such as those involving MNAR,
sensitivity analysis might represent the only possible
approach to account for the uncertainty due to the miss-
ingness in a principled way. However, due to the lack of
studies either performing a SA or providing high quality
scores on the assumptions, we argue that missingness is not
adequately addressed in most studies. This could have the
serious consequence of imposing too restrictive assump-
tions about missingness and affect the outcome of the
decision-making process.
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We suggest that authors may use Table 1 as a conve-
nient tool to check that all relevant information on missing
data is taken into account in determining the assumptions
in the analysis. All the key considerations should be fully
satisfied, if possible. These criteria summarise previously
published missing data recommendations from various
settings, drawing them together within a general, simple
and easy-to-read checklist table.
The classification of the studies into ordered categories
(Fig. 2) according to the information provided on missing
data (Table 1) is potentially a valuable tool for meta-
analysis. The proposed quality evaluation scheme could be
used by analysts to assign scores and grade individual
studies based on their overall quality level in terms of
missingness handling. These grades could then be taken
into account in assigning different weights to the individual
studies within the meta-analysis framework, in order to
reflect a different degree of confidence in their results.
7.3 Conclusions
Given the common problem of missing effect and cost data
in within-trial CEAs, many study conclusions could be
based on imprecise economic evidence. This is a poten-
tially serious issue for bodies such as the National Institute
for Health and Care Excellence (NICE) who use these
evaluations in their decision making, thus possibly leading
to incorrect policy decisions about the cost-effectiveness of
new treatment options.
Our review shows, over time, a significant change from
more to less restrictive methods in terms of the assump-
tions on the missingness mechanism. This is an encour-
aging movement towards a more suitable and careful
missing data analysis. Nevertheless, improvements are still
needed, as only a small number of articles provide trans-
parent information or perform a sensitivity analysis.
Our guidelines could represent a valuable tool to
improve missing data handling. By carefully thinking about
each component in the analysis, we are forced to explicitly
consider all the assumptions we make about missingness
and assess the impact of their variation on final conclu-
sions. The main advantage is a more comparable formali-
sation of the uncertainty as well as a better indication of
possible issues in assessing the cost-effectiveness of new
treatments.
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